Identity recordFDA-reviewed unapproved peptide identity
What KPV resolves to
KPV is tracked as an unapproved tripeptide identity with preclinical and laboratory evidence. FDA states that neither KPV free base nor KPV acetate is a component of an FDA-approved drug and that it found no published study in which a KPV drug product was administered to humans. A seller listing, formulation, or research label cannot establish clinical benefit, safety, local authorization, or lawful supply.
- Evidence lane
- FDA-reviewed unapproved peptide identity
- Current record
- No FDA-approved KPV drug and no identified human administration study
- Checked
- July 20, 2026
Lys-Pro-Vallysine-proline-valineMSH 11-13alpha-MSH 11-13KPV peptide